AUPH

Aurinia has crossed the line every commercial-stage biopharma chases: durable, profitable growth off one approved drug. LUPKYNIS net product sales grew 25% to $271.3M on "further LN market penetration" (per MD&A), total revenue rose 20.4% to $283M, and the company swung from a -$4.7M operating loss in 2024 to +$104.9M operating income — a real 37.1% operating margin at 88% gross margin. The swing was driven as much by cost discipline as by sales: SG&A fell from $172.0M to $101.8M and restructuring from $23.1M to $1.6M. Operating cash flow of $136M (+205.6%) confirms the earnings are cash, not accounting. The balance sheet is clean — liabilities/equity 0.29x, $581M equity, no meaningful leverage — and management is returning capital aggressively, spending $98.2M on buybacks and shrinking the share count 3.2%.

The critical caveat: the headline $287M net income and $2.07 diluted EPS are misleading. Pre-tax income was only $114.2M; the rest is a one-time $173.0M income-tax BENEFIT (deferred-tax-asset recognition against the -$649M accumulated deficit) that will not recur. So the stated 8.1 P/E and 101.5% net margin overstate the case. Normalize on ~$114M pre-tax earnings power against the $2.23B cap and you get a real multiple closer to ~19-20x — still fair-to-attractive for a 20-25% top-line grower throwing off $136M of operating cash.